1. Antidepressant effects of ketamine and the roles of AMPA glutamate receptors and other mechanisms beyond NMDA receptor antagonism;Aleksandrova;J. Psychiatry Neurosci.,2017
2. Axsome Therapeutics Announces Positive Efficacy and Safety Results from Phase 3 COMET Long-Term Trial and COMET-AU Trial of AXS-05 in Major Depressive Disorder. 2021;Axsome Therapeutics Inc,2020
3. Axsome Therapeutics Announces AXS-05 Achieves Primary and Key Secondary Endpoints in the MERIT Phase 2 Trial in Treatment Resistant Depression;Axsome Therapeutics Inc,2021
4. Intranasal esketamine (spravato(TM)) for use in treatment-resistant depression in conjunction with an oral antidepressant;Bahr;P T,2019
5. Combination of intravenous S-ketamine and oral tranylcypromine in treatment-resistant depression: a report of two cases;Bartova;Eur. Neuropsychopharmacol. (Netherlands),2015